The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The patient perspective of polycythemia vera and second-line treatment options
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, discusses a session she was involved in focused on the patient perspective of living with polycythemia vera (PV) and treatment options for patients who fail first-line treatment. She mentions several clinical trials investigating treatment for this patient population (RESPONSE: NCT01243944; RESPONSE-2: NCT02038036; MAJIC-PV: ISRCTN61925716) and expresses optimism for the future of PV. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Novartis, BMS, GSK; Speaker Bureau: Novartis, GSK, Incyte; Clinical Trial Support: BMS.
